According to the Innovation Medical announcement, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for three consecutive trading days from January 5 to 7, 2026, which is an abnormal fluctuation in stock trading. After verification, there are no major changes in the information disclosed by the company in the early stages. There have been no major changes in the company's production and operation situation or internal and external business environment recently, and the company, controlling shareholders and actual controllers have no important matters that should have been disclosed but not disclosed. The company reminds investors to invest rationally and pay attention to investment risks.

According to the Innovation Medical announcement, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for three consecutive trading days from January 5 to 7, 2026, which is an abnormal fluctuation in stock trading. After verification, there are no major changes in the information disclosed by the company in the early stages. There have been no major changes in the company's production and operation situation or internal and external business environment recently, and the company, controlling shareholders and actual controllers have no important matters that should have been disclosed but not disclosed. The company reminds investors to invest rationally and pay attention to investment risks.